NDLI: Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis.

Please wait, while we are loading the content...

A two-night comparison in the sleep laboratory as a tool to challenge the relationship between sleep initiation, cardiophysiological and thermoregulatory changes in women with difficulties initiating sleep and thermal discomfort.

Responses of Eastern red-backed salamanders (Plethodon cinereus) to chemical cues of prey presented in soluble and volatile forms.

Prenatal exposure to stressful life events is associated with masculinized anogenital distance (AGD) in female infants.

Validity and reliability of Polar® RS800CX heart rate monitor, measuring heart rate in dogs during standing position and at trot on a treadmill.

Intermittent access to sweet high-fat liquid induces increased palatability and motivation to consume in a rat model of binge consumption.

Having your cake and eating it too: a habit of comfort food may link chronic social stress exposure and acute stress-induced cortisol hyporesponsiveness.

Cardio-autonomic control and wellbeing due to oscillating color light exposure.

Low home cage social behaviors in BTBR T+tf/J mice during juvenile development.

Behavioral effects of combined environmental enrichment and chronic nicotine administration in male NMRI mice.

Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis.

Fimbria-fornix and entorhinal cortex differential contribution to contextual and cued fear conditioning consolidation in rats.

Year: 2013 Volume: 116-117

Year: 2012 Volume: 108

Year: 2012 Volume: 107

Year: 2012 Volume: 106

Year: 2012 Volume: 105

Year: 2011 Volume: 105

Year: 2011 Volume: 104

Year: 2011 Volume: 103

Year: 2011 Volume: 102

Year: 2010 Volume: 101

Year: 2010 Volume: 100

Year: 2010 Volume: 99

Year: 2009 Volume: 98

Year: 2009 Volume: 97

Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Dixit, Tejashree S. Sharma, Ajaykumar N. Lucot, James B. Elased, Khalid M.
Description	Country affiliation: India Author Affiliation: Dixit TS ( Department of Pharmacology, S.T.E.S.s Smt. Kashibai Navale College of Pharmacy, Kondhwa (Bk), Pune, MS 411048, India.)
Abstract	Recent studies indicate a high comorbidity between type-2 diabetes mellitus (T2DM) and neurological disorders. Many are associated with abnormalities in dopamine neurotransmission such as schizophrenia. Because most of the antipsychotic drugs aggravate pre-existing insulin resistance in type-2 diabetics, there is a need to search for alternative antipsychotics. Glucagon like peptide-1 (GLP-1) is a gut hormone primarily involved in glucose homeostasis. GLP-1 agonist (liraglutide) and dipeptidyl peptidase-IV (DPP-IV) inhibitor (sitagliptin) are the US-FDA approved medications for the management of T2DM. However, little is known about their role in dopamine mediated neurological disorders like schizophrenia. To address this, we used apomorphine-induced cage climbing behavior as a murine model for psychosis and examined for potential antipsychotic-like effect of liraglutide and sitagliptin. While acute liraglutide treatment (50 µg/kg; i.p.) significantly attenuated apomorphine (3 mg/kg, s.c.) induced cage climbing, sitagliptin (50mg/kg; i.p.) failed to elicit such effect. This is the first preclinical evidence for antipsychotic-like effect of GLP-1 receptor agonist. These results open an opportunity to explore GLP-1 analogs for their potential to modulate spectrum of dopamine-mediated neurological disorders.
File Format	HTM / HTML
ISSN	00319384
Volume Number	114-115
e-ISSN	1873507X
Journal	Physiology & Behavior
Language	English
Publisher	Elsevier
Publisher Date	2013-04-10
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Toxicity Drug Therapy Male Glucagon-like Peptide 1 Therapeutic Use Apomorphine Journal Article Dopamine Agonists Pyrazines Discipline Physiology Antipsychotic Agents Animals Triazoles Etiology Statistics, Nonparametric Psychotic Disorders Mice Sitagliptin Phosphate Discipline Behavioral Neuroscience Analogs & Derivatives Liraglutide Disease Models, Animal
Content Type	Text
Resource Type	Article
Subject	Experimental and Cognitive Psychology Behavioral Neuroscience

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

Inkretintengelyen ható gyógyszerek a 2-es típusú diabetes kezelésében.

Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.

Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats

Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.

Effects of the glucagon-like peptide-1 (GLP-1) analogues exenatide, exenatide extended-release, and of the dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin on glucose metabolism in healthy cats.

Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.

Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis.

Similar Documents

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

Inkretintengelyen ható gyógyszerek a 2-es típusú diabetes kezelésében.

Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.

Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats

Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.

Effects of the glucagon-like peptide-1 (GLP-1) analogues exenatide, exenatide extended-release, and of the dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin on glucose metabolism in healthy cats.

Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.

Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis.